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There was no reduction in N. meningitidis carriage density in 4CMenB vaccinated students compared 
to unvaccinated students 12 months post vaccination, despite increased carriage clearance. Higher 






Higher density of Neisseria meningitidis carriage may be associated with transmission of the 
meningococcus. Our aim was to establish the impact of 4CMenB vaccine on N. meningitidis carriage 
density.  
Methods 
We compared 4CMenB vaccine to control among 913 South Australian students aged approximately 
15-18 years in a cluster randomized trial who had N. meningitidis carriage at 12 months. 
Oropharyngeal swabs were collected at baseline and 12 months later to detect N. meningitidis 
carriage. Colony forming units per millilitre (CFU/ml) were estimated by generating a standard curve 
that plotted qPCR cycle threshold values against log-normalized CFU.  
Results  
Among the 913 students with N. meningitidis carriage at 12 months, there was no difference in 
mean carriage density between the vaccinated (n=434, 3.80 log CFU/ml [SD 1.29]) and control group 
(n=479, 3.73 log CFU/ml [SD 1.30]; p=0.51). Higher N. meningitidis carriage density at baseline was 
associated with an increase in the odds of persistent carriage at 12 months (n=504, odds ratio per 
1.0 log CFU/ml increase in density = 1.36 [95% CI, 1.17, 1.58], p<0.001). Students with baseline 
carriage who were vaccinated had decreased persistent N. meningitidis carriage at 12 months 
compared to unvaccinated students (82/186 [31%] vs 105/186 [43%], odds ratio 0.60 [95% CI, 0.40, 
0.90], p=0.01) 
Conclusion 
4CMenB vaccine did not reduce carriage density of N. meningitidis 12 months post vaccination, 
despite increased carriage clearance. Higher carriage density is likely to enable transmission through 











Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, remains an 
important cause of morbidity and mortality worldwide.[1, 2] Serogroups A, B, C, W, X, or Y 
are most commonly associated with disease.[1] A high proportion of IMD cases are due to 
serogroup B, this is especially so in Australia, Europe, North America, and South America.[3] 
Asymptomatic pharyngeal carriage of N. meningitidis is common in the general 
population.[4] A large meta-analysis reports that N. meningitidis carriage prevalence 
increases in children and peaks around 19 years of age at approximately 24%.[5] Carriage 
prevalence in university settings especially in the Americas and European region is 
consistently high.[6] Serogroup B has been responsible for 11 outbreaks of IMD among 
university students and close contacts between 2008 and 2017 in the United States (US).[7, 
8] In each outbreak since 2013, recombinant meningococcal vaccines have been used, as 
well as chemoprophylaxis of close contacts.[8]  
The relationship between carriage and disease is not entirely clear.[9] However, a study of 
21,000 teenagers aged 15-19 years in the United Kingdom (UK) recently reported a halving 
of N. meningitidis carriage rates over a 15 year duration, consistent with the reduction in 
disease incidence.[10] Changes in carriage prevalence may occur though natural variation, 
alteration in risk factors for carriage such as smoking, and social contact, [5, 10, 11] or 
introduction of meningococcal vaccines.[12]  Lower than anticipated carriage prevalence in 
Australian university students (6.2%) was thought to be associated with low rates of 
cigarette smoking.[13] Carriage prevalence of less than 10% has also been observed in other 




Two novel recombinant vaccines Bexsero 4CMenB (GSK) and Trumenba MenB-FHbp (Pfizer) 
are now licenced in USA, Canada, Europe, and Australia against serogroup B disease. Recent 
randomized controlled trials provide evidence that 4CMenB has limited impact on the 
carriage prevalence and acquisition of disease-causing N. meningitidis in adolescents, 
including group B.[15, 19] Clearance of existing carriage may be important in populations 
with very high carriage prevalence or for outbreak responses.    
Reporting N. meningitidis carriage just as absence / presence may miss potentially 
important reductions in carriage density that could be relevant when investigating vaccine 
impact. This is because reducing the density of bacteria colonising the pharynx may reduce 
the risk of transmission. Density of N. meningitidis pharyngeal carriage varies, with the 
majority of those colonised having relatively small amounts of bacteria present.[20, 21] 
Pneumococcal conjugate vaccines have demonstrated a reduction in carriage density of 
vaccine-type strains of pneumococci in a small number of studies,[22-24] but not all.[25, 26] 
Mucosal immune responses to recombinant vaccines may be different to that of conjugate 
vaccines.[27] To date, the impact of meningococcal vaccines on carriage density has not 
been established.  
The impact of 4CMenB vaccine on carriage are important considerations for cost-
effectiveness, implementation of vaccine programs, and future vaccine design. The aims of 
this study are to: 1) establish the impact of 4CMenB vaccine on N. meningitidis carriage 
density, 2) identify if carriage density is associated with persistence of carriage, 3) establish 
the impact of 4CMenB vaccine on carriage persistence, and 4) identify associations between 







This analysis was derived from an investigator led, cluster randomized controlled trial 
designed to examine the impact of 4CMenB vaccine on carriage of disease-causing 
meningococci in adolescent school students.[15, 28] Participating schools were randomized 
to 4CMenB vaccination at baseline (intervention) or 12 months (control). The trial was 
sponsored by The University of Adelaide, designed and overseen by an Independent 
Scientific Advisory Committee and conducted in South Australia between 2017 and 2018 
with support by a research grant from GlaxoSmithKline. Ethical approval was granted by the 
Women’s and Children’s Health Network Human Research Ethics Committee 
(HREC/16/WCHN/140). 
Procedures/Measurements 
All 260 secondary schools in metropolitan, rural, and remote South Australia were invited to 
participate in the trial. Year 10 and 11 students were followed up in schools at 12 months, 
whereas the year 12 students only provided baseline data.  
Oro-pharyngeal swabs were collected from the posterior pharynx using a standardised 
technique by trained nursing and medical staff using sterile flocked swabs at baseline 
(2017), and repeated at 12 months for year 10 and 11 students (2018).[15] The swabs were 
placed into vials containing 2 mL of skim milk, tryptone, glucose, and glycerol (STGG) 
transport medium (Thermo Scientific). A questionnaire designed to assess risks factors for 
carriage was completed prior to each swab collection.[28]  
Each specimen was subjected to real-time PCR (rt-PCR) screening for the presence of 




with cycle threshold (Ct) values ≤50 were considered detected. Further rt-PCR analysis was 
used on porA positive specimens to determine the genogroup of N. meningitidis detected 
(A, B, C, W, X, Y). They were classified as non-groupable if the capsule biosynthesis genes for 
these genogroups were not detected. Specimens with a positive porA PCR were cultured 
and resulting strains of N. meningitidis had whole genome sequencing analysis using 
methods described elsewhere.[13] Clonal complex is assigned based on the sequence type 
of the Neisseria meningitidis by their similarity to a central allelic profile according to the 
PubMLST database.[29] 
To convert Ct values to an estimate of colony forming units (CFU) per ml, N. meningitidis 
siaD B positive stock control was cultured out and a suspension equal to a 0.5 McFarland 
turbidity standard was made. Serial dilutions were performed and plated out (4 plates per 
dilution), these were then diluted 1:1 with lysis buffer. Samples were then extracted and 
subjected to porA PCR (8x per dilution). A standard curve was plotted using qPCR Ct values 
against log-normalized value of colony forming units of N. meningitidis. 
Statistical Analysis 
As this analysis is exploratory and involves the secondary use of data already collected in the 
high school RCT, no pre-specified sample size calculation was undertaken.  
To investigate the effects of 4CMenB vaccination on carriage density, the mean difference in 
log CFU/ml between groups was estimated in students with carriage detected at 12 months. 
CFU/ml estimations were highly positively skewed so log transformations were used to 
better approximate the normal. Comparisons were made for any N. meningitidis, disease-
causing N. meningitidis, and non-groupable N. meningitidis carriage density. The analyses 




to account for clustering at the school level.  The association between overall carriage 
density at baseline and persistence of carriage 12 months later (yes/no) was evaluated using 
logistic GEEs, with adjustment for treatment group.  All analyses were performed using Stata 
v14.[30]   
RESULTS 
Characteristics of participants 
Baseline characteristics of the students that participated in the randomised control trial are 
described in Supplementary Table 1. 237 schools agreed to participate and 24,269 year 10 
and 11 students (approximately 15-16 years) and 10,220 year 12 students (approximately 
17-18 years of age) were enrolled following informed consent. Swabs were collected at visit 
one between 1st April - 30th June 2017, and visit two 1st February - 13th of July 2018. Both 
periods encompass autumn and the first month of winter. The mean length of time between 
swab 1 and swab 2 was 366 days (SD 24 days). Carriage data were available for 21,126 year 
10 and 11 students at 12 months (87%) following the withdrawal of 43 students and loss to 
follow-up of 3,100 students. Overall N. meningitidis carriage at 12 months was 4.32%. 
Students with carriage at 12 months (n=913) were included in this density analysis (Figure 
1). Of the 913 in this cohort, 423 (46%) were in year 10 and 490 (54%) were in year 11. For 
the analysis of baseline density and persistence of carriage, 504 participants (of a total of 
658 who had carriage at baseline) who returned at 12 months were included, with 186/504 
(37%) showing persistent carriage (Figure 1). Carriage density was similar for any N. 
meningitidis between 2017 (n=658, 3.70 log CFU/ml [SD 1.35]) and 2018 (n=913, 3.76 log 





Carriage density (vaccinated vs. unvaccinated) 
Carriage density of any N. meningitidis at 12 months was similar (Figure 2) between the 
vaccinated (n=434, 3.80 log CFU/ml [SD 1.29]) and control group students (n=479, 3.73 log 
CFU/ml [SD 1.30], difference = 0.07 [95% CI -0.13 to 0.26]; p=0.51).The observed densities of 
disease-causing N. meningitidis by individual genogroups (B, C, W, and Y) and for non-
groupable N. meningitidis were also similar between the vaccinated and control students 
(Table 1). Of the 10,220 year 12 students participating in the high school RCT, 3,719 (36.4%) 
provided a 12- month swab as part of a separate cross-sectional school leaver study. A 
sensitivity analysis that included an extra 351 year 12 students with carriage detected at 12 
months was consistent with the analysis of year 10s and 11s (Supplementary Table 2). 
There was no significant difference in the carriage density of the two most common Clonal 
Complex groups causing invasive disease in South Australia, group B Clonal Complex 41/44 
(vaccinated n=29, 4.23 log CFU/ml [SD 1.32] versus unvaccinated n=26, 4.07 log CFU/ml [SD 
1.36], difference  0.15 [95% CI, -0.51 to 0.82]; p=0.65) and group B Clonal Complex 32 
(vaccinated n=28,  4.65 log CFU/ml [SD 0.83] versus unvaccinated n=24, 4.69 log CFU/ml [SD 
1.13], difference -0.04 [95% CI, -0.55 to 0.47]; p=0.88).  
Density at baseline and carriage persistence (carriage persistence vs. loss) 
Approximately 37% (186/504) of participants with N. meningitidis carriage at baseline had 
persistent carriage at 12 months. For each one unit increase in the baseline log density 
measure, independently of treatment group the odds of having persistent N. meningitidis 
carriage increased by 36% (n=504, OR 1.36 [95% CI, 1.17 to 1.58], <0.001). A similar 
association was also present for disease-causing N. meningitidis carriage density (Table 2). 




at the 12 month visit as the baseline visit (group B 43/58 [74%], group C 2/2 [100%], group 
W 1/4 [25%], group Y 24/35 [69%], and non-groupables 77/88 [88%]).  
Independent of baseline carriage density, students with baseline carriage who were 
vaccinated had decreased N. meningitidis carriage persistence at 12 months compared to 
unvaccinated students (Table 3). The decreased persistence was mostly in non-groupable N. 
meningitidis. Students with carriage detected at baseline who did not return for a 12 month 
swab (n=154) were more likely to be in the vaccinated group, smoke cigarettes and/or 
water-pipes, be older or have kissed someone in the last week compared to those who 
returned at 12 months. However, adjusting for these (predominantly fully observed) 
predictors of loss to follow-up in a sensitivity analysis had little impact on results. 
Risk factors for carriage density  
In a multivariable model, higher year level and kissing one or more people in the last week 
were associated with higher carriage density of any N. meningitidis at baseline. Identifying 
as ‘other’ ethnicity was associated with a reduced carriage density (Table 4). 
DISCUSSION 
This secondary analysis of students with carriage from a large cluster-randomized controlled 
trial did not find evidence of an impact of 4CMenB vaccine on N. meningitidis carriage 
density. Students with higher carriage density at baseline were more likely to have 
persistent carriage of N. meningitidis at 12 months. Although not an unexpected finding, it 
adds weight to the importance of reducing carriage density. Not only will reducing carriage 
density potentially decrease the risk of transmission, it is likely to also shorten the duration 




Salivary antibodies are thought to be key to reducing acquisition and colonization of N. 
meningitidis. Salivary IgA and IgG antibodies have been shown to peak at approximately 1 
month and wane considerably 6 to 12 months following meningococcal conjugate and 
polysaccharide vaccination.[27, 31, 32] In a longitudinal study in the United Kingdom, 
pharyngeal swabs and saliva samples were taken from 416 students (295 completed three 
visits). Students received 4CMenB at visit 1 and 2, mean carriage density fell from 70 gene 
copies/ml in Sept-Dec to 34 gene copies/ml in Jan-March.[33] This small uncontrolled pilot 
study had a 3 month interval between vaccination and swabbing. In our cohort, it is possible 
that we may have missed a shorter impact on carriage density due to the longer 12 month 
interval between swabs.  
Risk factors for N. meningitidis carriage in adolescents are reasonably well established but 
rarely examined in relation to carriage density. The association of kissing at least one person 
in the last week and higher carriage density is similar to carriage studies that have assessed 
the impact of social factors on carriage prevalence.[10, 11, 15] The numbers of participants 
smoking cigarettes, e-cigarettes, and water pipes were too small to draw any conclusions for 
these activities. Unlike previous studies that have investigated social risk factors for 
carriage,[10, 11, 18] age/year of schooling remained associated with carriage density after 
adjusting for social factors. This is similar to the findings of the RCT, where school year 
remained associated with carriage after adjusting for social risk factors.[15] In a carriage 
study in The Gambia, pharyngeal swabs were collected from 999 pupils aged 10 to 18 years 
with no association identified between age and N. meningitidis density.[34]  
With only one 12 month time point in this study it is not possible to assess the average 




baseline had carriage detected at 12 months. The mean duration of carriage calculated in a 
longitudinal study of Belgian children was approximately 11.7 months. Serogroup B and C 
had the longest mean duration of carriage, 16.2 months and 18 months respectively.[35] 
There was minimal change of genogroup in those with persistent carriage in our cohort.  
It is of interest that there is a modest increase in carriage clearance in vaccinated students 
compared to unvaccinated students who had carriage at baseline. However, the clearance is 
greatest for non-groupable N. meningitidis. An exploratory analysis reported the risk of non-
groupable N. meningitidis carriage was 29% lower in the vaccinated group than control 
group at 12 months.[15] Our finding indicates that the reduction at 12 months is due to a 
combination of clearance of carriage, as well as reduced acquisition. It remains unclear what 
role non-groupable N. meningitidis have in preventing acquisition of disease-causing N. 
meningitidis. Whilst it’s possible that non-groupable carriage has some role in producing 
protective SBA titers, it is generally accepted that the most important correlate of 
protection against meningococcal infection is the presence of serum bactericidal activity 
against the invasive strain.[36, 37] In populations with low carriage prevalence similar to 
South Australia, it is likely that a much larger impact on clearance would be required to 
result in significantly reduced carriage prevalence. This is especially the case with carriage 
acquisition being similar between the vaccinated and unvaccinated students at 12 months 
following vaccination in our cohort.[15]  
With saliva IgA and IgG circulation likely to peak approximately one month after vaccination, 
it is possible that this resulted in increased clearance of N. meningitidis from oral mucosa, 
without a lasting impact on acquisition after the initial antibody peak. Loss to follow up of 




caution needs to be taken when assessing the outcomes in relation to persistent carriage. 
The loss of 23% is close to double that of the year 10 and 11 cohort as a whole (12%).[15] 
Similar to this study, in a pilot longitudinal study we have previously reported that students 
at higher risk of carriage are more likely to be lost to follow up.[13] It is possible that 
carriage clearance is over estimated with those more likely to have carriage at 12 months 
excluded from this analysis. However, results were unchanged when predominantly fully 
observed baseline predictors of missing data were adjusted for.  
The greatest limitation when examining carriage density is the variability in sampling and 
testing. The sensitivity of swabbing is estimated to be between 60–83%.[38] We used 
standard operating procedures and trained medical and nursing staff in swab technique to 
maximize consistency. Whilst some variation is to be expected, it is not likely to favor either 
the vaccinated or control groups.  
In this study, the majority of participants had carriage density >50 CFU/ml, which is higher 
than previously reported.[20, 21] This is most likely due to inter-laboratory variation, 
including the use of porA primers designed specifically for this study, to maximise detection 
of N. Meningitidis carriage. Previous density studies have often used ctrA qPCR or sodC 
qPCR, which potentially have less sensitivity when used as the sole target primer. [39, 40] 
Within this study sample, the same qPCR testing methods were used and therefore 
differences between the vaccinated and unvaccinated groups are not affected. 
Overall, the results of this study show that higher density is associated with persistent 
carriage. Important risk factors for higher carriage density are increasing year of schooling, 




vaccinating students will reduce carriage density of disease-causing N. meningitidis 12 
months following vaccination.  
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Mean Difference  
(95% CI)* P-Value 
Any carriage 434 3.80 (1.29)  479 3.73 (1.30) 0.07 (-0.13 to 0.26) 0.51 
Disease-causing†  255 3.95 (1.24) 250 3.91 (1.19) 0.04 (-0.19 to 0.27) 0.72 
- Genotype B 124 3.98 (1.20) 114 4.01 (1.23) -0.03 (-0.33 to 0.27) 0.85 
- Genotype C 12 3.65 (0.89) 7 4.22 (0.90) -0.58 (-1.39 to 0.23) 0.16 
- Genotype W 17 3.35 (1.46) 18 4.15 (1.14) -0.80 (-1.60 to 0.01) 0.05 
- Genotype Y 95 4.05 (1.28) 113 3.76 (1.16) 0.29 (-0.15 to 0.73) 0.20 
Non-groupable 179 3.57 (1.33) 229 3.53 (1.38) 0.04 (-0.28 to 0.36) 0.80 
* Linear regression, with generalized estimating equations used to account for clustering at the 





Table 2: Odds of persistent carriage at 12 months per 1.0 log CFU/ml increase in baseline density 






carriage n (%) Odds Ratio (95% CI) P-Value 
Any Carriage 504 186 (37%) 1.36 (1.17 to 1.58) <0.001 
Disease-causing 255 98 (38%) 1.29 (1.03 to 1.62) 0.03 
- Genotype B 138 58 (42%) 1.18 (0.87 to 1.60) 0.28 
- Genotype Y 99 35 (35%) 1.35 (0.96 to 1.90) 0.08 
Non-groupable 249 88 (35%) 1.40 (1.16 to 1.69) <0.001 
* Logistic regression, with generalized estimating equations used to account for clustering at the 
school level, within individuals, and adjusted for treatment group. † Groups C and W were not 






 Table 3: Proportion of year 10 and 11 students with persistent N. meningitidis carriage (yes/no) at 
12 months, by vaccinated and unvaccinated groups. 
 




Odds Ratio (95% CI) P-value 
Any carriage  81 (31) 105 (43) 0.60 (0.40 to 0.90) 0.01 
Disease-causing 44 (36)  54 (41) 0.83 (0.50 to 1.37) 0.46 
- Genogroup B 28 (38)  30 (46) 0.73 (0.37 to 1.44)  0.36 
- Genogroup C 1 (100)  1 (17) - - 
- Genogroup W 1 (17)  3 (38) 0.33 (0.26 to 4.25)  0.40 
- Genogroup Y 15 (35) 20 (36) 0.96 (0.45 to 2.05)  0.93 
Non-groupable 37 (27) 51 (46) 0.43 (0.23 to 0.80) 0.01 
 
Logistic regression, with generalized estimating equations used to account for clustering at the 




Table 4: Multivariable analysis of risk factors for carriage density of any N .meningitidis in 10s 11s 






Adjusted log CFU/ml 




Year of schooling 10 281 (23) 3.49 (1.32) 1 0.02* 
 11 378 (31) 3.85 (1.35) 0.32 (0.10 to 0.55) 0.004 
 12 563 (46) 3.85 (1.29) 0.23 (0.01 to 0.45) 0.04 
Sex Female 633 (52) 3.75 (1.34) 1  
 Male 589 (48) 3.78 (1.30) 0.04 (-0.12 to 0.20) 0.61 
School ICSEA category† <970 (low) 262 (21) 3.55 (1.27) 1 0.11* 
 970 to 1020 (medium) 357 (29) 3.79 (1.32) 0.21 (0.00 to 0.43) 0.05 
 >1020 (high) 603 (49) 3.84 (1.34) 0.20 (-0.03 to 0.42) 0.09 
School size <60 students/year  200 (16) 3.86 (1.36) 1 0.34* 
 60 to 119 students/year  403 (33) 3.80 (1.31) -0.12 (-0.44 to 0.19) 0.44 
 >119 students/year  619 (51) 3.71 (1.32) -0.21 (-0.51 to 0.09) 0.17 
School location Metropolitan 861 (70) 3.78 (1.31) 1  
 Rural  361 (30) 3.72 (1.35) -0.07 (-0.29 to 0.15) 0.53 
Antibiotics Not taken in the past month 1,031 (85) 3.78 (1.31) 1 0.17* 
 Taken in the last month 80 (7) 3.90 (1.53) 0.13 (-0.23 to 0.49) 0.49 
 Stopped in the last week 43 (4) 3.72 (1.27) -0.10 (-0.53 to 0.34) 0.66 
 YES, currently taking 58 (5) 3.38 (1.36) -0.38 (-0.72 to -0.03) 0.03 
Current cold or sore throat  327 (27) 3.73 (1.40) 0.00 (-0.17 to 0.18) 0.96 
Cigarette in the last week  96 (8) 3.67 (1.19) -0.06 (-0.41 to 0.29) 0.75 
E-cigarette in the last week  39 (3) 3.63 (1.27) -0.05 (-0.41 to 0.32) 0.80 
Water-pipe in the last week  116 (10) 3.78 (1.27) 0.11 (-0.20 to 0.42) 0.49 
Out in last week   452 (37) 3.92 (1.33) 0.12 (-0.06 to 0.31) 0.20 
Kissing in last week  487 (41) 3.93 (1.31) 0.22 (0.05 to 0.40) 0.01 
Boarding student  54 (4) 3.68 (1.44) -0.15 (-0.55 to 0.25) 0.47 
Ethnicity Caucasian 903 (76) 3.84 (1.31) 1 0.04* 
 Aboriginal/TSI‡ 61 (5) 3.53 (1.32) -0.09 (-0.49 to 0.31) 0.66 
 Asian 64 (5) 3.44 (1.42) -0.36 (-0.74 to 0.03) 0.07 
 Other§ 165 (14) 3.57 (1.29) -0.23 (-0.45 to -0.02) 0.03 
* Global p-value, † Index of Community Socio-Educational Advantage, ‡ Aboriginal and/or Torres 
Strait Islander, § Combined with Middle Eastern, Pacific Islander, and African because of the small 





Figure 1: Flow of subjects recruited in the study and included in the density analysis. 
 
Figure 2: Estimated CFU/ml density by vaccination status at 12 months 
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 Supplementary Appendix 
Supplementary Table 1. Baseline characteristics for year 10 and 11 students.  
Characteristic Vaccinated group  Unvaccinated group 
 N=12746 N=11523 
School ICSEA category: n (%)*   
<970 (low) 2175 (17.06) 2471 (21.44) 
970 to 1020 (medium) 3763 (29.52) 3601 (31.25) 
>1020 (high) 6808 (53.41) 5451 (47.31) 
School size: n (%)   
<60 students/year (small) 2112 (16.57) 1536 (13.33) 
60 to 119 students/year (medium) 4181 (32.80) 3903 (33.87) 
>119 students/year (large) 6453 (50.63) 6084 (52.80) 
School location: n (%)   
Metropolitan 9829 (77.11) 8147 (70.70) 
Rural 2917 (22.89) 3376 (29.30) 
Age - years: mean (sd) 15.6 ( 0.7) 15.6 ( 1.2) 
Sex: n (%)   
Female 6670 (52.33) 5795 (50.29) 
Male 6076 (47.67) 5728 (49.71) 
Year of schooling: n (%)   
10 6576 (51.59) 6188 (53.70) 
11 6170 (48.41) 5335 (46.30) 
Smoking (cigarettes/day): n/ total n (%)   
None 12457/12666 (98.35) 11273/11454 (98.42) 
1-5 153/12666 ( 1.21) 140/11454 ( 1.22) 
6-10 37/12666 ( 0.29) 32/11454 ( 0.28) 
>10 19/12666 ( 0.15) 9/11454 ( 0.08) 
Currently taking antibiotics: n/ total n (%) 620/12589 ( 4.92) 574/11374 ( 5.05) 
Boarding student: n/ total n (%) 340/12686 ( 2.68) 190/11469 ( 1.66) 
Smoked e-cigarette in last week: n/ total n (%) 127/12626 ( 1.01) 127/11,408 ( 1.11) 
Smoked water-pipe in last week: n/ total n (%) 369/12626 ( 2.92) 281/11406 ( 2.46) 
Ethnicity: n/ total n (%)   
Caucasian 9089/12509 (72.66) 7962/11314 (70.37) 
Aboriginal and/or Torres Strait Islander 366/12509 (2.93) 313/11314 (2.77) 
Asian 1216/12509 (9.72) 1173/11314 (10.37) 
Other 1838/12509 (14.69) 1866/11314 (16.49) 
 
* Index of Community Socio-Educational Advantage  
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Mean Difference * 
(95% CI)  
P-
Value 
Any carriage (607) 3.96 [1.33] (657) 3.92 [1.36] 0.04 (-0.14 to 0.21) 0.67 
Disease-causing†  (360) 4.12 [1.24] (345) 4.11 [1.27] 0.01 (-0.19 to 0.21) 0.93 
- Genotype B (164) 4.12 [1.24] (152) 4.16 [1.25] -0.03 (-0.30 to 0.23) 0.80 
- Genotype C (19) 3.98 [0.94] (16) 4.25 [1.40] -0.26 (-1.02 to 0.50) 0.50 
- Genotype W (25) 3.65 [1.50] (29) 4.27 [1.17] -0.62 (-1.27 to 0.03) 0.06 
- Genotype Y (147) 4.22 [1.23] (151) 4.04 [1.29] 0.18 (-0.18 to 0.54) 0.32 
Non-groupable (247) 3.73 [1.41] (312) 3.72 [1.43] 0.01 (-0.25 to 0.30) 0.91 
* Linear regression, with generalized estimating equations used to account for clustering at the school level, † 
Disease-causing refers to all capsular genotypes identified (B, C, W, X, Y).  
 
 
 
 
